title: Efficacy and tolerability of a prolonged release ferrous sulphate formulation in iron deficiency anaemia: a non-inferiority controlled trial.
abstract: BACKGROUND
  Iron deficiency anaemia (IDA) is the last stage of iron deficiency, consecutive to an imbalance between iron supply through food intake and iron loss through physiological or pathological processes. As well as by haemoglobin levels, IDA is diagnosed by measuring biomarkers of iron stores. Women are most affected by IDA since their teenage years, as menstruation constitutes a chronic iron loss. Oral supplementation with ferrous sulphate is an effective therapy, but gastrointestinal side effects may impair treatment compliance.
  
  
  METHODS
  The present multicentric randomised controlled trial was designed to assess the non-inferiority of a ferrous sulphate prolonged release formulation called V0355 with the referential ferrous sulphate Ferrograd® in a population of Italian women aged 18-50 years diagnosed for IDA. Three hundred and ninety-nine patients were randomised to receive V0355 (80 mg Fe/day) or Ferrograd® (105 mg Fe/day).
  
  
  RESULTS
  After 12 weeks of treatment, the difference in the mean haemoglobin level between the two groups was 0.081 g/dL ([-2.986;1.361], p = 0.54), which confirmed the hypothesis of non-inferiority. All the other biochemical parameters (serum iron, serum ferritin, transferrin, and soluble transferrin receptor) and haematological parameters (erythrocytes count, reticulocytes count, haematocrit, and mean corpuscular volume), as well as patient's anaemia-related symptoms, were not different between treatment groups throughout the study. Furthermore, the incidence of gastrointestinal adverse events of moderate and severe intensity was significantly lower (p = 0.007) in the V0355 group (5.6%) than in the Ferrograd® group (13.9%).
  
  
  CONCLUSIONS
  V0355 was as efficient as Ferrograd® in the treatment of anaemia and exhibited a better gastrointestinal tolerance profile.
authors.affiliation: Institut de Recherche Pierre Fabre, Pierre Fabre Innovation, 3 Avenue Hubert Curien, Toulouse Cedex 1, France. mohammed.zaim@pierre-fabre.com
authors.forename: Mohammed
authors.initials: M
authors.lastname: Zaim
authors.forename: Leonardo
authors.initials: L
authors.lastname: Piselli
authors.forename: Pino
authors.initials: P
authors.lastname: Fioravanti
authors.forename: Claire
authors.initials: C
authors.lastname: Kanony-Truc
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000494:pharmacology / Q000627:therapeutic use; D019587:Dietary Supplements; D004311:Double-Blind Method; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D019266:Iron, Dietary / Q000008:administration & dosage* / Q000097:blood; D008875:Middle Aged; D011247:Pregnancy; D015995:Prevalence; D011446:Prospective Studies; D017701:Reticulocyte Count; D014168:Transferrin / Q000378:metabolism; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003692:Delayed-Action Preparations; D005296:Ferrous Compounds; D006454:Hemoglobins; D019266:Iron, Dietary; D014168:Transferrin; C020748:ferrous sulfate; D005293:Ferritins